Acura Pharmaceuticals Inc.
01/20/2026 | Press release | Distributed by Public on 01/20/2026 15:16
Material Agreement (Form 8-K)
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
| Date | Principal |
Aggregated Principal |
||||||||
| Original Secured Promissory Note | 11/10/2022 | $ | 2,319,279 | $ | 2,319,279 | |||||
| Additional Loans to be included: | ||||||||||
| Loans #1 dated 12/22/2022 through Loan #38 dated 6/20/2025 | $ | 5,875,000 | $ | 8,194,279 | ||||||
| Loan #39 | 7/03/2025 | $ | 100,000 | $ | 8,294,279 | |||||
| Loan #40 | 7/18/2025 | $ | 100,000 | $ | 8,394,279 | |||||
| Loan #41 | 8/01/2025 | $ | 100,000 | $ | 8,494,279 | |||||
| Loan #42 | 8/15/2025 | $ | 100,000 | $ | 8,594,279 | |||||
| Loan #43 | 9/03/2025 | $ | 100,000 | $ | 8,694,279 | |||||
| Loan #44 | 9/12/2025 | $ | 100,000 | $ | 8,794,279 | |||||
| Loan #45 | 10/06/2025 | $ | 100,000 | $ | 8,894,279 | |||||
| Loan #46 | 10/23/2025 | $ | 100,000 | $ | 8,994,279 | |||||
| Loan #47 | 11/12/2025 | $ | 100,000 | $ | 9,094,279 | |||||
| Loan #48 | 11/21/2025 | $ | 100,000 | $ | 9,194,279 | |||||
| Loan #49 | 12/12/2025 | $ | 100,000 | $ | 9,294,279 | |||||
| Loan #50 | 12/31/2025 | $ | 100,000 | $ | 9,394,279 | |||||
| Loan #51 | 1/02/2026 | $ | 100,000 | $ | 9,494,279 | |||||
| Loan #52 | 1/16/2026 | $ | 100,000 | $ | 9,594,279 | |||||
ACURA PHARMACEUTICALS, INC.
| By: | /s/ Robert A. Seiser | |
| Robert A. Seiser | ||
| Senior Vice President & CFO | ||
| Date: January 16, 2026 | ||
Acura Pharmaceuticals Inc. published this content on January 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 20, 2026 at 21:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]